Protagonist Therapeutics Reports $213.5M Revenue Growth and $162.8M Net Income in Latest Quarter

Protagonist Therapeutics, Inc. reported significant financial growth in its latest quarterly filing, with license and collaboration revenue soaring to $213.5 million for the three months ended June 30, 2026, compared to just $5.5 million in the same period last year. This remarkable increase is attributed primarily to a $200 million opt-out payment from Takeda Pharmaceuticals, alongside a $50 million milestone payment from Janssen Biotech, Inc. for the FDA approval of ICOTYDE™ (icotrokinra) for treating moderate-to-severe plaque psoriasis. The company also recorded a net income of $162.8 million for the quarter, a substantial turnaround from a net loss of $34.8 million in the prior year.

In terms of operational metrics, Protagonist's total assets increased to $885.5 million as of June 30, 2026, up from $668.2 million at the end of 2025. The company's cash and cash equivalents rose significantly to $420.1 million, compared to $128.7 million at the end of the previous fiscal year. This financial stability is bolstered by a decrease in total liabilities, which fell to $44 million from $53.5 million, reflecting improved cash management and operational efficiency.

Strategically, Protagonist has made notable advancements in its product pipeline. The company is actively developing ICOTYDE, which is also in Phase 3 trials for additional indications, including psoriatic arthritis and ulcerative colitis. Furthermore, rusfertide, another key product, is under priority review by the FDA, with a target action date set for August 2026. The company has also expanded its workforce, increasing its research and development headcount to 108 from 100 year-over-year, indicating a commitment to enhancing its clinical development capabilities.

Looking ahead, Protagonist anticipates continued growth in revenue driven by upcoming milestones and royalties from its collaboration agreements. The company expects to leverage its strong cash position to fund ongoing research and development activities, particularly as it advances multiple candidates through clinical trials. Management has expressed confidence that the existing cash reserves will be sufficient to support operations for at least the next twelve months, although they remain open to future funding opportunities to further expand their product pipeline.

Overall, Protagonist Therapeutics is positioned for a promising trajectory, with a solid financial foundation, a robust pipeline of innovative therapies, and strategic partnerships that could yield significant revenue in the coming years.